BBIO - BridgeBio Pharma, Inc.
IEX Last Trade
27.96
0.330 1.180%
Share volume: 16,124
Last Updated: Fri 27 Dec 2024 06:30:23 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.40%
PREVIOUS CLOSE
CHG
CHG%
$27.63
0.33
1.19%
Fundamental analysis
31%
Profitability
37%
Dept financing
25%
Liquidity
73%
Performance
16%
Performance
5 Days
2.74%
1 Month
7.90%
3 Months
16.54%
6 Months
21.10%
1 Year
-32.06%
2 Year
262.06%
Key data
Stock price
$27.96
DAY RANGE
$27.60 - $28.80
52 WEEK RANGE
$22.94 - $41.80
52 WEEK CHANGE
-$31.76
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail

CEO: Neil Kumar
Region: US
Website: bridgebio.com
Employees: 400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: bridgebio.com
Employees: 400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a stabilizer of transthyretin, or TTR.
Recent news